One of the most interesting unanswered questions in melanoma research is the paradoxical observation that melanomas among older patients have a different natural history and survival outcome compared with middle-aged and younger melanoma patients. Since 1978, a number of studies have published studies demonstrating that patient age is an independent predictive factor of melanoma survival, and that patient age independently predicts the incidence of sentinel node metastases among clinically node-negative patients. [1] [2] [3] [4] In this issue of the Annals of Surgical Oncology are two interesting articles analyzing patient age and the incidence of nodal metastases among melanoma patients. 5, 6 Using the Surveillance, Epidemiology, and End Results Program (SEER) population-based database of 47,577 melanoma patients, Cavanaugh-Hussey and colleagues found that older melanoma patients had a higher mortality rate and a lower incidence of sentinel node metastases compared with younger patients. 5 This fascinating inverse relationship between sentinel node metastasis rate and patient age was first described in 2004 by Chao et al. 7 and Sondak et al. 8 We recently analyzed outcomes of 7756 patients from the American Joint Committee on Cancer (AJCC) Melanoma Staging database and found that primary melanomas became more advanced with increasing age by decadetumors were thicker, exhibited higher mitotic rates, and were more likely to be ulcerated-and that patient age was an independent predictor of sentinel node metastases in a multifactorial analysis (p \ 0.00012). 2 However, survival results from both our studies and that of CavanaughHussey found, paradoxically, a significant decrease in the incidence of sentinel node metastasis as patient age increased, and an increased mortality compared with younger patients.
Do these conclusions mean that we should be more conservative in our recommendations to older patients? Not according to the second study published in this month's issue of Annals of Surgical Oncology by Sabel and colleagues who analyzed the outcomes of 952 melanoma patients 75 years of age or older from the University of Michigan Melanoma Database. 6 The incidence of sentinel node metastases was 25 % among patients selected for surgery in the Michigan study, whereas the incidence of sentinel node metastases in the AJCC study was lower at 15.5 % for patients C80 years of age. 6 How can we reconcile these differences?
Both the SEER and AJCC melanoma databases are more representative of national patient populations, whereas the University of Michigan database may reflect 'referral bias' that is inherent to patients referred to a regional academic referral center. Thus, patients who were more frail or debilitated might not have been able to make the journey to a regional referral center. When reporting our results, those of us in academic referral centers need to be cognizant that our patient population is not necessarily reflective of that in a community-based practice. In addition, there is the physician judgment and experience that greatly influences our surgical recommendations as to whether older patients might benefit from this staging procedure and undergo an operation safely. This 'physician expert' bias is not necessarily reflected in current measurements of patient frailty. Thus, the Charleston Frailty Index in the study by Sabel et al. did not influence the decision to conduct a sentinel lymph node biopsy, most likely because this frailty index does not represent all the issues of co-morbidity that we, as surgeons, take into account when making recommendations regarding surgery.
It is also interesting that the Michigan study identified the sentinel node procedure itself as an independent prognostic factor, with patients not having a sentinel node biopsy having lower survival rates. Is this a treatment effect of biopsy-directed lymphadenectomy or a surgeon selection effect where the surgeon's judgment and intuition selected patients who were medically fit to have more extensive surgery and, conversely, patients at greater risk had more conservative treatment? The study by Sabel et al. included all patients 75 years of age and older, with melanomas of C1.0 mm in thickness (i.e. T2, T3, and T4 melanomas) and with clinically negative regional lymph nodes. Their results are more likely due to surgeon selection and less unlikely this is a treatmentrelated survival benefit based upon results of two randomized surgical trials. In the Intergroup Melanoma randomized trial comparing elective lymphadenectomy versus observation among melanomas of 1.0-4.0 mm in thickness, the survival benefit of surgery in pre-determined cohorts was confined to patients under 60 years of age who did not have an ulcerated melanoma. 9 The Multicenter Selective Lymphadenectomy Trial-1 (MSLT1) surgical trial only demonstrated a survival benefit in the predetermined cohort of melanomas between 1.2 and 3.5 mm thickness, but not among thicker melanomas. 10 Unless the Michigan melanoma data subsequently demonstrates that their survival benefit was confined to patients with intermediate thickness melanomas, it is difficult to conclude that the surgical intervention of biopsydirected lymphadenectomy directly resulted in a survival benefit. On the other hand, I have always thought that we have not accounted for 'surgeon judgment' as a prognostic factor that no doubt influences survival outcomes of surgical treatment in ways that we have not yet been able to quantify.
Unfortunately, older patients generally do not have the same standards of care applied as younger patients, and this may a contributing factor that is hard to quantify. Thus, using the National Cancer Database in 2008-2009, Bilimoria and colleagues found that patients older than 75 years of age were less likely to have a sentinel node biopsy compared with younger patients and, furthermore, that only half of the patients with sentinel node metastases underwent a completion lymphadenectomy. 11, 12 Sentinel node biopsy use was not only associated with clinicalpathological features but also with health system factors, including the type of insurance, geographic area, and hospital type. 11 Patients were significantly less likely to undergo a completion lymphadenectomy if they were older that 75 years of age or had lower extremity melanomas (i.e. requiring a groin dissection). 12 Similarly, the CavanaughHussey study also found that there were a significantly greater proportion of older patients who ''did not have any lymph node surgery among the older population (77 % for older patients vs. 52 % for younger population [p \ 0.0001])''. 5 Care of the older melanoma patient presents many challenges related to the different biology of cancer in older persons, different host biology of older persons, and co-morbidities that certainly influence treatment selections and survival outcome. The explanation for the difference in melanoma outcomes among older patients is likely to be multifactorial. Primary melanomas in the very young and in the elderly population may have differing biological features, alternative routes of metastasis, and/or divergent host responses to the metastatic process, especially with regard to immune competence, and these differences may contribute to the observed differences in mortality rates. 13 Older patients are also more likely to have differences in access to, and application of, healthcare resources. This is an important public health issue because the largest increase in incidence and mortality of melanoma is in the older population. Compared with other cancers in the USA, there is a disproportionate increase in mortality in melanoma patients aged 65 years or older, particularly among men.
14 Mortality among older men increased by over 157 % from 1969 to 1999, while their incidence increased fivefold compared with a threefold increase for women of the same age group. 15 From a policy standpoint, melanoma care presents a significant economic burden among the elderly population in the USA. 16 Cancer staging partitions patients into cohorts with a similar risk for harboring metastatic disease. Staging is a major criterion for selecting cancer treatment; therefore, accurate and complete staging is an essential first step in planning multidisciplinary management. Clinical staging is highly inaccurate, especially in melanoma, and thus microstaging of the primary melanoma and pathological staging of clinically negative regional lymph nodes for micrometastases are now 'standard of care' for higher risk melanoma patients, even among the elderly population. [17] [18] [19] If we understage, and therefore undertreat, older melanoma patients, we may miss the opportunity to extend their life, and also to embark later on with an even more expensive series of treatments with systemic agents when they progress to stage IV melanoma. Thus, as a fundamental principle of clinical surgery, we should make our recommendations for surgical staging and treatment when the benefits outweigh the risks. This includes the older population of patients where we should assess this risk/ benefit ratio based upon the individual patient's physiological condition and co-morbidities, not upon their chronological age.
These data exemplify the heterogeneity of melanoma and the diversity of clinical outcomes that must be accounted for by both clinicians and investigators. The outcomes data consistently demonstrates an increased mortality for older melanoma patients, especially males. Is this due to biological differences compared with younger patients or undertreatment? We do not know. The interactions between biological, clinical, and social factors resulting in this paradox are provocative and support an interesting series of hypotheses to be tested in future studies.
